Zacks Research Issues Pessimistic Forecast for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at Zacks Research cut their Q2 2026 EPS estimates for Denali Therapeutics in a research report issued on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of ($0.75) per share for the quarter, down from their prior estimate of ($0.74). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.54) per share. Zacks Research also issued estimates for Denali Therapeutics' Q3 2026 earnings at ($0.73) EPS and FY2026 earnings at ($2.90) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. During the same quarter last year, the firm earned $1.30 earnings per share. The company's revenue was down 99.7% compared to the same quarter last year.

Several other research analysts have also weighed in on the stock. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Bank of America upped their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Citigroup upped their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Finally, Cantor Fitzgerald downgraded shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $38.22.

Denali Therapeutics Stock Performance

DNLI traded down $0.29 on Friday, hitting $26.15. 410,048 shares of the company were exchanged, compared to its average volume of 1,082,439. The business's fifty day moving average is $27.04 and its 200 day moving average is $22.73. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13. The firm has a market capitalization of $3.73 billion, a P/E ratio of -27.24 and a beta of 1.38.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. MONECO Advisors LLC lifted its position in shares of Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock worth $265,000 after buying an additional 400 shares during the last quarter. Integrated Advisors Network LLC bought a new stake in Denali Therapeutics in the 3rd quarter valued at about $283,000. China Universal Asset Management Co. Ltd. lifted its position in Denali Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,535 shares of the company's stock valued at $802,000 after purchasing an additional 10,782 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Denali Therapeutics in the 3rd quarter valued at about $288,000. 92.92% of the stock is currently owned by institutional investors.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Ryan J. Watts sold 40,000 shares of the firm's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares of the company's stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.90% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.